Q-omics provides the consensus-scored TMEM210 profile across patient tissues and cancer cell-line models. TMEM210 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, TMEM210 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, TMEM210 RNA expression shows 8,965 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, HNSC, and THYM as cancer lineages where TMEM210 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM210 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM210 survival associations across molecular data types. TMEM210 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM210 RNA expression–survival associations across cancer types. High TMEM210 expression shows unfavorable associations in UCS, KIRP, KIRC, MESO and ACC, but favorable associations in UCEC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for TMEM210 RNA expression.
This table summarizes TMEM210 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM210. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM210 shows lower tumor expression in HNSC and higher tumor expression in UCEC, BRCA, BLCA, LUAD and PRAD. The HNSC box plot shows higher TMEM210 RNA expression in normal versus tumor tissue (log2 FC = −0.364, t-test p = .001).
This table shows molecular features associated with TMEM210 in patient tissues and cancer cell lines. In patient samples, TMEM210 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM210 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
